Comprehensive. Life-Saving. Time Saving.
Transplant-associated thrombotic microangiopathy (TA-TMA) occurs when endothelial injury in the context of allogeneic hematopoietic cell transplantation (allo-HCT) causes microangiopathic hemolytic anemia and platelet consumption, resulting in microvascular thrombosis and fibrin deposition in the microcirculation.
Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of stem cell transplants that can occur with peripherally mobilized stem cells or bone marrow-derived stem cells.
Contact us to learn more about the TA-TMA assays
33334 - TA-TMA CH50 33335 - TA-TMA sC5b-9 33336 - TA-TMA Eculizumab
Eurofins Viracor's TA-TMA testing stands out for its comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9. Our comprehensive approach ensures that clinicians receive detailed results across all three critical areas, empowering them to make informed decisions about patient treatment promptly, thanks to our industry-leading 24 hour turnaround time.
Transplant Associated Thrombotic MicroAngiopathy
Eurofins Viracor's TA-TMA (Transplant-associated thrombotic microangiopathy) testing stands out for its comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9.